LON:FAB Fusion Antibodies (FAB) Share Price, News & Analysis → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free FAB Stock Alerts GBX 3.65 -0.10 (-2.67%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range 3.50▼ 3.7050-Day Range 3.65▼ 4.1852-Week Range 3.02▼ 50Volume167,778 shsAverage Volume1.15 million shsMarket Capitalization£3.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesInsider TradesStock AnalysisChartCompetitorsHeadlinesInsider Trades Get Fusion Antibodies alerts: Email Address Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Fusion Antibodies Stock (LON:FAB)Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. It serves pharmaceutical, biotech, and diagnostic companies. The company has a collaboration partnership with Celonic AG. The company was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.Read More FAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FAB Stock News HeadlinesFebruary 27, 2024 | msn.comResearch Reveals Conserved Neutralizing Epitope in Herpesvirus gB ProteinFebruary 22, 2024 | uk.investing.comFusion Antibodies PLC (FAB)April 28, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.February 2, 2024 | lse.co.ukFusion Antibodies gets tax credit from UK HMRC for OptiMAL platformJanuary 22, 2024 | lse.co.ukFusion Antibody Share ChatJanuary 17, 2024 | msn.comHIV antibodies protect animals in proof-of-concept studyJanuary 9, 2024 | morningstar.comFusion Antibodies PLC Ordinary Shares FABJanuary 8, 2024 | msn.comStudy suggests omicron subvariant causes enhanced fusion with human lung cellsApril 28, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.December 20, 2023 | markets.businessinsider.comFusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% UpsideNovember 28, 2023 | marketwatch.comFusion Antibodies Shares Rise on US Cancer Institute CollaborationNovember 9, 2023 | msn.comBelfast antibodies firm Fusion flags up 'challenges'October 31, 2023 | news.yahoo.comNew cancer therapy using antibody could offer a less toxic treatment option, study showsOctober 1, 2023 | finance.yahoo.comFusion Antibodies Full Year 2023 Earnings: UK£0.10 loss per share (vs UK£0.046 loss in FY 2022)September 29, 2023 | marketwatch.comFusion Antibodies Pretax Loss Widens on Higher Costs, Lower RevenueAugust 23, 2023 | markets.businessinsider.comIntroducing NeoMab™: GemPharmatech's Innovative Antibody Gene Humanized Mouse ModelAugust 21, 2023 | marketwatch.comFusion Antibodies Signs Combined Screening Service With AI CompanyAugust 16, 2023 | finance.yahoo.comTonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy VolunteersMay 19, 2023 | marketwatch.comFusion Antibodies Shares Dive After Discounted PlacingMay 16, 2023 | marketwatch.comAntibody Engineering Services Market Growth, Business Overview 2023, and Forecast to 2030 | Fusion Antibodies, Absolute Antibody, Creative BiolabsApril 28, 2023 | forbes.comResurrection Of Covid Antibody Therapy: IgG3 Fc Fusion To The RescueApril 27, 2023 | marketwatch.comAntibody Engineering Services Market Growth by 2031April 20, 2023 | marketwatch.comAntibody Engineering Services Market Projected Industry Expansion and Factors Impacting Competitors, Alongside Promising Strategies Until 2029April 19, 2023 | marketwatch.comRecombinant Therapeutic Antibodies and Proteins Market: Key Players and Strategies for Future Growth by 2023-2030April 13, 2023 | msn.comFusion (FUSN) to Begin Clinical Study on Targeted Alpha TherapyMarch 21, 2023 | marketwatch.comFusion Antibodies Files Patent Application for Cancer Treatment AntibodiesMarch 15, 2023 | foxnews.comSleep deprivation could reduce vaccine antibodies, new study foundSee More Headlines Receive FAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fusion Antibodies and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:FAB CUSIPN/A CIKN/A Webfusionantibodies.com Phone+44-28-90432800FaxN/AEmployees48Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-2,840,000.00 Net Margins-179.67% Pretax MarginN/A Return on Equity-140.93% Return on Assets-62.52% Debt Debt-to-Equity Ratio3.23 Current Ratio3.26 Quick Ratio2.36 Sales & Book Value Annual Sales£1.58 million Price / Sales2.20 Cash FlowGBX 0.40 per share Price / Cash Flow9.02 Book ValueGBX 2 per share Price / Book1.83Miscellaneous Outstanding Shares95,370,000Free FloatN/AMarket Cap£3.48 million OptionableNot Optionable Beta0.66 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Adrian Robert Kinkaid Ph.D. (Age 57)CEO & Director Comp: $183.49kDr. Richard John Buick Ph.D. (Age 48)Chief Scientific Officer & Director Comp: $127kProf. Jim JohnstonFounderMr. Stephen Barry Smyth (Age 50)Company Secretary, Interim CFO & Director Ms. Nicola HamiltonOperations ManagerDr. Paul Gerard Kerr (Age 51)Consultant Comp: $180.38kMore ExecutivesKey CompetitorsOxford Cannabinoid TechnologiesLON:OCTPAptamer GroupLON:APTAMotif BioLON:MTFBIXICOLON:IXIValiRxLON:VALView All CompetitorsInsidersSimon Gordon DouglasBought 100,565 shares on 12/4/2023Total: £502,825.00 ($5.00/share)Richard John BuickBought 68,750 shares on 6/9/2023Total: £481,250.00 ($7.00/share)View All Insider Transactions FAB Stock Analysis - Frequently Asked Questions How have FAB shares performed in 2024? Fusion Antibodies' stock was trading at GBX 4.25 at the beginning of the year. Since then, FAB shares have decreased by 14.1% and is now trading at GBX 3.65. View the best growth stocks for 2024 here. What other stocks do shareholders of Fusion Antibodies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Antibodies investors own include D4t4 Solutions (D4T4), Aminex (AEX), Eurasia Mining (EUA), Dril-Quip (DRQ), 4D pharma (DDDD), ABM Industries (ABM), Card Factory (CARD), Blockchain Worldwide (BLOC), ATTRAQT Group (ATQT) and How do I buy shares of Fusion Antibodies? Shares of FAB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:FAB) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHis win rate puts Warren Buffett to shame… Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Antibodies plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
